Amgen To Pay $780M To Settle Drug Sales Suits

Law360, New York (October 24, 2011, 10:50 PM EDT) -- Amgen Inc. said Monday it would pay $780 million to settle allegations over its sales and marketing practices stemming from civil and criminal investigations — including Medicaid claims and a whistleblower suit accusing the drugmaker of bribing health care providers to buy its drug Aranesp.

In a third-quarter statement, Amgen said the proposed settlement amount would resolve the qui tam suit launched by ex-Amgen employee Kassie Westmoreland, as well as nine other whistleblower suits, state Medicaid claims and criminal and civil investigations conducted by U.S. attorney's...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.